ダウンロード数: 17
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s13287-024-03691-7.pdf | 6.16 MB | Adobe PDF | 見る/開く |
タイトル: | iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva |
著者: | Gao, Pan Inada, Yoshiko Hotta, Akitsu Sakurai, Hidetoshi Ikeya, Makoto |
著者名の別形: | 稲田, 与志子 堀田, 秋津 櫻井, 英俊 池谷, 真 |
キーワード: | Fibrodysplasia ossificans progressiva Heterotopic ossification Induced pluripotent stem cells Mesenchymal stem/stromal cells ACVR2B-Fc fusion protein |
発行日: | 18-Mar-2024 |
出版者: | Springer Nature BMC |
誌名: | Stem Cell Research & Therapy |
巻: | 15 |
論文番号: | 83 |
抄録: | Background: Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease caused by a gain-of-function mutation in ACVR1, which is a bone morphogenetic protein (BMP) type I receptor. Moreover, it causes progressive heterotopic ossification (HO) in connective tissues. Using FOP patient-derived induced pluripotent stem cells (FOP-iPSCs) and mouse models, we elucidated the underlying mechanisms of FOP pathogenesis and identified a candidate drug for FOP. Methods: In the current study, healthy mesenchymal stem/stromal cells derived from iPSCs (iMSCs) expressing ACVR2B-Fc (iMSC[ACVR2B-Fc]), which is a neutralizing receptobody, were constructed. Furthermore, patient-derived iMSCs and FOP mouse model (ACVR1[R206H], female) were used to confirm the inhibitory function of ACVR2B-Fc fusion protein secreted by iMSC[ACVR2B-Fc] on BMP signaling pathways and HO development, respectively. Results: We found that secreted ACVR2B-Fc attenuated BMP signaling initiated by Activin-A and BMP-9 in both iMSCs and FOP-iMSCs in vitro. Transplantation of ACVR2B-Fc-expressing iMSCs reduced primary HO in a transgenic mouse model of FOP. Notably, a local injection of ACVR2B-Fc-expressing iMSCs and not an intraperitoneal injection improved the treadmill performance, suggesting compound effects of ACVR2B-Fc and iMSCs. Conclusions: These results offer a new perspective for treating FOP through stem cell therapy. |
記述: | iMSCによるACVR2B-Fc融合タンパク質の送達は進行性骨化性線維異形成症モデルマウスの異所性骨化を抑制する. 京都大学プレスリリース. 2024-03-26. Instructing iPS cell-derived mesenchymal stem cells (iMSCs) to inhibit abnormal bone formation in Fibrodysplasia Ossificans Progressiva. 京都大学プレスリリース. 2024-03-26. |
著作権等: | © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. |
URI: | http://hdl.handle.net/2433/287579 |
DOI(出版社版): | 10.1186/s13287-024-03691-7 |
PubMed ID: | 38500216 |
関連リンク: | https://www.cira.kyoto-u.ac.jp/j/pressrelease/news/240326-100000.html https://www.cira.kyoto-u.ac.jp/e/pressrelease/news/240326-100000.html |
出現コレクション: | 学術雑誌掲載論文等 |
このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス